Latest filings (excl ownership)
15-12B
Securities registration termination
9 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
25-NSE
Exchange delisting
31 Jan 18
8-K
Completion of Acquisition or Disposition of Assets
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
SC 14D9/A
Tender offer solicitation (amended)
30 Jan 18
SC TO-T/A
Third party tender offer statement (amended)
30 Jan 18
8-K
Repros Announces Negative Opinion From the EMA for Enclomiphene
26 Jan 18
SC 14D9
Tender offer solicitation
26 Jan 18
SC 14D9/A
Tender offer solicitation (amended)
19 Jan 18
SC 14D9/A
Tender offer solicitation (amended)
5 Jan 18
SC TO-T/A
Third party tender offer statement (amended)
5 Jan 18
SC TO-T/A
Third party tender offer statement (amended)
4 Jan 18
SC 14D9/A
Tender offer solicitation (amended)
3 Jan 18
SC 14D9
Tender offer solicitation
29 Dec 17
SC TO-T
Third party tender offer statement
29 Dec 17
8-K
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
15 Dec 17
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 17
SC14D9C
Written communication relating to third party tender offer
15 Dec 17
SC14D9C
Written communication relating to third party tender offer
13 Dec 17
8-K
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
12 Dec 17
10-Q
2017 Q3
Quarterly report
13 Nov 17
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 17
8-K
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
13 Nov 17
8-K
Departure of Directors or Certain Officers
13 Oct 17
8-K
Submission of Matters to a Vote of Security Holders
15 Sep 17
8-K
REPROS THERAPEUTICS Corporate Presentation September 2017 Dedicated to Treating Male and Female Reproductive Disorders
11 Sep 17
Latest ownership filings
SC 13G/A
Repros Therapeutics Inc.
14 Feb 19
SC 13G/A
Repros Therapeutics Inc.
13 Feb 18
4
Katherine Anderson
31 Jan 18
4
Michael Wyllie
31 Jan 18
4
PATRICK FOURTEAU
31 Jan 18
4
Saira Ramasastry
31 Jan 18
4
DANIEL F CAIN
31 Jan 18
4
Nola E Masterson
31 Jan 18
SC 13G
Repros Therapeutics Inc.
2 Jan 18
SC 13G/A
Repros Therapeutics Inc.
2 Jan 18
4
Nola E Masterson
18 Sep 17
4
Saira Ramasastry
18 Sep 17
4
PATRICK FOURTEAU
18 Sep 17
4
Michael Wyllie
18 Sep 17
4
DANIEL F CAIN
18 Sep 17
SC 13G
Repros Therapeutics Inc.
24 Jul 17
4
Katherine Anderson
5 Jul 17
4
Katherine Anderson
2 Jun 17
4
Katherine Anderson
1 May 17
4
Katherine Anderson
4 Apr 17
4
Katherine Anderson
2 Mar 17
4
Nola E Masterson
15 Feb 17
4
Michael Wyllie
15 Feb 17
4
PATRICK FOURTEAU
15 Feb 17
4
DANIEL F CAIN
15 Feb 17
4
Saira Ramasastry
15 Feb 17
SC 13G/A
Repros Therapeutics Inc.
14 Feb 17
3
Larry Dillaha
13 Feb 17
4
Katherine Anderson
3 Feb 17
4
JOSEPH PODOLSKI
9 Dec 16
4
Nola E Masterson
23 Nov 16
4
J. F. Wernicke
6 Jul 16
4
Jaye Thompson
6 Jul 16
4
Saira Ramasastry
5 Jul 16
4
PATRICK FOURTEAU
5 Jul 16
4
Michael Wyllie
5 Jul 16
4
Nola E Masterson
5 Jul 16
4
DANIEL F CAIN
5 Jul 16
3
PATRICK FOURTEAU
16 May 16
4
PATRICK FOURTEAU
16 May 16